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Abstract
Severe acute respiratory syndrome (SARS) is a highly lethal emerging disease caused by coronavirus
SARS-CoV. New lethal animal models for SARS were needed to facilitate antiviral research. We
adapted and characterized a new strain of SARS-CoV (strain v2163) that was highly lethal in 5–6
week old BALB/c mice. It had nine mutations affecting 10 amino acid residues. Strain v2163
increased IL-1α, IL-6, MIP-1α, MCP-1, and RANTES in mice, and high IL-6 expression correlated
with mortality. The infection largely mimicked human disease, but lung pathology lacked hyaline
membrane formation. In vitro efficacy against v2163 was shown with known inhihibitors of SARSCoV replication. In v2163-infected mice, Ampligen™ was fully protective, stinging nettle lectin
(UDA) was partially protective, ribavirin was disputable and possibly exacerbated disease, and
EP128533 was inactive. Ribavirin, UDA and Ampligen™ decreased IL-6 expression. Strain v2163
provided a valuable model for anti-SARS research.
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Introduction
Severe acute respiratory syndrome (SARS) emerged in 2002 in the Guandong province of
southern China as a new infectious respiratory disease characterized by influenza-like
symptoms and signs, but with a very high mortality rate (Ksiazek et al., 2003; Peiris et al.,
2003b). A novel coronavirus termed SARS-CoV was identified as the etiological agent
(Drosten et al., 2003a; Drosten et al., 2003b). The World Health Organization (WHO) reported
8,098 SARS cases from November 2002 to July 2003, and approximately 10% of the patients
died (http://who.int/csr/sars/country/table2003_09_23/en/). Subsequent outbreaks including
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two laboratory events occurred, but they were rapidly contained. These outbreaks demonstrated
the need for strategies to treat sporadic cases of SARS disease, including economical lethal
rodent models that would simulate human SARS disease.
Studies on the molecular evolution of SARS-CoV suggested that the virus emerged from nonhuman sources (Guan et al., 2003), although the natural reservoir of the virus has not been
positively identified. A current hypothesis is that the horseshoe bat is the main natural reservoir
of SARS-CoV-like viruses (Hon et al., 2008; Li et al., 2005b). A number of SARS-CoV-like
viruses have been isolated from bats, although the full lineage for the ancestors of SARS-CoV
remains uncharacterized (Hon et al., 2008). Virus transmission to humans may have occurred
when civet cats, infected by bats, were traded on Chinese wet markets (Guan et al., 2003).
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Severe SARS-CoV infections in humans are characterized by diffuse alveolar damage and
sparse inflammatory infiltrates (Chen and Subbarao, 2007; Franks et al., 2003; Nicholls et al.,
2003). Hyaline membrane formation is a hallmark of SARS-CoV lung damage in humans
(Hsiao et al., 2005). In addition to the hyaline membrane formation in severe SARS cases,
findings could include serous, fibrinous and hemorrhagic inflammation in pulmonary alveoli
with capillary engorgement, including micro-thrombosis in some of these capillaries (Lang et
al., 2003). Pulmonary alveoli are thickened with interstitial mononuclear inflammatory
infiltrates. Desquamation of pneumocytes can be detected along with fibrinoid materials, and
erythrocytes in alveolar spaces (Lang et al., 2003). Cell types in the respiratory tract in which
SARS-CoV antigen has been detected include the following: alveolar epithelial cells (primarily
type II pneumocytes), bronchial epithelial cells, and alveolar macrophages (Ding et al., 2004;
Ye et al., 2007). These cell types all have the angiotensin-converting enzyme 2 (ACE2), which
has been identified as one of the receptors to which SARS-CoV binds in order to be taken up
into host cells (Li et al., 2005a; 2003).
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A number of animal species have been proposed to model SARS infections in human, including
macaques (Fouchier et al., 2003), marmosets (Greenough et al., 2005), mice (Glass et al.,
2004; Roberts et al., 2005), golden Syrian hamsters (Roberts, 2006), rats (Nagata et al.,
2007), cats (Martina et al., 2003; van den Brand et al., 2008), and ferrets (Chu et al., 2008;
Martina et al., 2003; Subbarao and Roberts, 2006; van den Brand et al., 2008). The utility of
various animal models has been extensively reviewed by Roberts and Subbarao (2006). Briefly,
the non-primate models do not exactly model the lung pathology found in humans. For
example, hyaline membrane formation is not seen at all or rarely detected. In the rodent models,
fever is also not detected. Nevertheless rodent models may be the most utile of the models
because of low expense, ease of handling, defined genetics, and the possibility of doing largescale statistically significant studies. Because of these advantages, a lethal rodent model would
be extremely valuable in antiviral drug testing where the amounts of experimental compound
available for evaluation in animals are often limited.
Since early in the SARS outbreak, there has been a concerted effort by many laboratories to
evaluate vaccines (Du et al., 2009) or to develop clinically approved drugs for efficacy against
SARS-CoV to rapidly provide a treatment for SARS infections in humans (Tong, 2009a; Tong,
2009b). To date, there is no approved agent for treating SAR-CoV and no agent has reached
human clinical trials (Wong and Yuen, 2008). This is due to lack of animal model testing among
other reasons. Ribavirin had been used to treat SARS infections in 2003 and 2004, but its
efficacy is questionable and it may exacerbate disease in mice (Barnard et al., 2006b) and
humans (Stockman, Bellamy, and Garner, 2006). Wu and others have recently reviewed the
state of drug discovery for SARS-CoV antiviral agents (Pyrc, Berkhout, and van der Hoek,
2007; Stockman, Bellamy, and Garner, 2006; Tong, 2009b; Wu et al., 2006; Yeung and
Meanwell, 2007). In the current study, we report on the pathogenesis and genetic changes of
a SARS-CoV strain, called v2163, which was adapted from SARS-CoV Urbani by 25 serial
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passages to cause a lethal pulmonary syndrome in 5–6 week old mice. Using multiple drugs
with purported antiviral activity, the utility of the new strain as a model virus for evaluating
drugs in cell culture and in mice is shown.

RESULTS
Morbidity and virus titers in mice
The Urbani strain of SARS-CoV, which is not lethal to BALB/c mice, was serially passaged
25 times in BALB/c mice at 3 day intervals and resulted in a highly lethal strain we designated
as v2163. The v2163 virus caused severe signs of illness in 5–6 week old BALB/c mice
including ruffled fur and lethargy within 3–4 days and death by day 6. Another lethal mouseadapted strain designated as MA15 (Roberts et al., 2007) was tested in parallel for comparison.
Both mouse-adapted strains caused substantial weight loss and produced high virus titers in
the lungs of infected mice (Table 1). In contrast, SARS-CoV strain Urbani-infected mice had
no significant weight loss compared with uninfected controls, although they had moderate virus
titers in the lungs three days post virus exposure as shown previously by Barnard et al.
(2006a; 2006b). Lung virus titers at 3 days post virus inoculation (d.p.i.) were higher in v2163infected mice than in MA15-infected mice. Lung titers did not appear dependent on the level
of virus inoculum, but did differ depending on the virus strain. The v2163 virus and MA15
virus persisted in the lungs for 6 days, while Urbani strain was below detection limit by day 6.
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Mortality and recovery in mice
Infection with v2163 resulted in 100% of the 5–6 week old mice losing 20% of their initial
weight, and 70% to 100% of mice dying depending on the infectious dose (Table 1). Nearly
all MA15-infected mice lost more than 20% of their initial weight when infected with 104.5 or
105.5 CCID50 (Table 1), confirming results observed in 6–8 week old mice by Roberts et al.
(2007). However, the v2163 strain killed more mice than strain MA15 regardless of the
inoculum used (Table 1). The v2163 virus was lethal at concentrations as low as 103.5
CCID50 per mouse. In a replicate experiment, results were similar to those in Table 1, except
6 of 10 mice receiving 104.5 CCID50 of MA15 died (Table 2). However, the MA15-infected
mice that died had a mean day of death (MDD) of 13.5 ± 6.9 days, compared with 5.9 ± 1.4
MDD for the corresponding v2163-infected group (Table 2). Overall, death of 6-week old mice
infected with v2163 was significantly greater (P <0.001) than MA15-infected mice (Figure 1).
Recovery from severe illness was more likely for MA15-infected mice than for v2163-infected
mice, and v2163 was lethal at a lower infectious dose. The average LD50 for v2163 was
103.3±0.3 CCID50 per mouse. These data were unique because, by special provision, animals
were not euthanized during severe illness but allowed to die or recover spontaneously.
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Age variability
The animal experiment was repeated comparing 5–6 week old mice with 10–11 week old mice
(Table 2). The older mice infected with MA15 lost more weight by 4 d.p.i. than corresponding
v2163-infected mice, and their MDD was 2–3 days later than v2163-infected mice. Mortality
in 10–11 week mice was high for both mouse-adapted virus strains using 105.5 and 104.5
CCID50 inocula. However, only 10% of the MA15-infected mice receiving the 103.5 inoculum
died, while 100% of the corresponding v2163-infected mice died. No mice died from Urbani
infection. Interestingly, in one separate age experiment, only 20% (2/10) of mice 3–4 weeks
old died from a 104.0–4.5 CCID50 v2163 infection, while 100% of 7–8 week old mice died (data
not shown). This supported the notion that SARS-CoV was more lethal in older hosts.
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The v2163 virus had 9 mutations, one of which affected two reading frames, resulting in
changes to 10 amino acid residues compared with the wild type Urbani. Four mutations
occurred in the spike protein (S) region (Figure 2). A putative G-A mutation was observed in
base pair 22722 with some replicates, but it was not found in RNA from infected mouse lungs.
The mutations were compared to the MA15 lethal strain (Roberts et al., 2007), revealing
interesting similarities and differences in the mutation spectra associated with mouse
adaptation in young Balb/c mice (Figure 2). In the structural genes, the Y436H mutation in the
v2163 spike region was conserved in strain MA15, and the M-mutation was in a similar location
on both lethal strains (S6L for v2163, E11K in MA15). In the replicase genes, the nsp9 mutation
(E4185D) was located near an nsp9 mutation (T4184A) found in strain MA15, and both lethal
strains had an nsp13 mutation.
Cytokines and chemokines
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The mouse-adapted strains of SARS-CoV elicited expression of cytokines IL-1α and IL-6, and
chemokines MIP-1α, MCP-1, and RANTES in the lungs of mice 3 days after infection as
measured with the multiplex ELISA assay (Figure 3). Levels of IL-1β, IL-2, IL-3, IL-4, IL-5,
IL-9, IL-10, TNF-α, and GM-CSF were below the minimum detection level for all test groups
(≤38 pg/mL of lung homogenate). Low levels of INF-γ were observed with both mouse-adapted
strains but not detected with the Urbani strain. Two out of ten v2163-inoculated mice showed
low cytokine response, and were excluded from cytokine analysis because they also had little
or no virus detected in their lungs. The MA15 virus stimulated significantly more MIP-1α, and
RANTES compared with Urbani (P < 0.05), and the v2163 virus caused significantly greater
MCP-1 response than Urbani (P < 0.01). A significantly higher IL-6 response compared with
the wild type Urbani strain was observed from both v2163 and MA15 mouse-adapted strains
(P <0.001, P < 0.05 respectively). The v2163-infected mice expressed 6-fold more IL-6 than
the MA15-infected mice. At the infection level used in this experiment, 100% of v2163infected mice died and no MA15-infected mice died, showing a correlation between IL-6
concentrations in the lungs and mortality.
Histopathology
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Three lung samples for each virus or control were evaluated for pathological changes 3 days
after inoculation by a board certified veterinary pathologist (Figure 4). Lungs of mice
inoculated with the Urbani strain of SARS-CoV showed no significant changes, and shaminfected controls showed no marked changes except some scattered dense granulomas in one
of three lungs. All three MA15-infected lungs showed small numbers of foamy macrophages
and small numbers of neutrophils. Alveolar septae were seen in two of the three MA15-infected
lungs. One MA15-infected lung had rare individual bronchiolar lining cells that were swollen
and hypereosinophilic and degenerate. Pathological changes were observed in two of the three
v2163-infected lungs; one had moderate numbers of neutrophils, edema fluid surrounding
several large vessels, and rare granulomas containing refractile central fragments of foreign
material replacing groups of alveoli. Another v2163-infected lung showed small numbers of
alveolar macrophages throughout airspaces. In general, lungs infected with MA15 or v2163
showed acute to subacute alveolitis with some perivascular edema in some sections (Figure
4). Differences between the two mouse-adapted strains were minimal. Hyaline membrane
formation, as occurs in human SARS patients (Roberts et al., 2005), was not observed.
In vivo efficacy of drugs against v2163 infection
To demonstrate the utility of the lethal mouse model for antiviral drug testing, we evaluated
the known antiviral agents ribavirin, an antiviral nucleoside analog (Sidwell et al., 1972), and
Ampligen™(poly I:poly C12U), a synthetic dsRNA polymer that induces interferon production
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(Barnard et al., 2006a; Carter et al., 1972; Gowen et al., 2007). We also evaluated the novel
drugs EP128533, a dipeptidyl glutaminyl fluoromethylketone protease inhibitor (Zhang et al.,
2006), and UDA, a lectin that impedes viral fusion and egress (Keyaerts et al., 2007).
Ampligen™ (10 mg/kg/d) afforded mice complete protection against death, reduced virus titers
in the lungs, and significantly reduced lung scores and weight loss (Table 3). UDA treatment
of 5 mg/kg/day resulted in 50% protection from death up to 10 days after infection (Table 3),
but no reduction in lung virus titer. A replicate 21-day study showed 40% protection and no
measurable toxicity with 15 mg/kg/d of UDA (data not shown). Protease EP128533 was
inactive in BALB/c mice.
Ribavirin treatment of 75 mg/kg/d did not significantly protect mice from death (Table 3).
Virus lung titers from mice treated with ribavirin were no different than those detected from
control mice on 3 d.p.i., but at 6 d.p.i. the titers in ribavirin- treated mice were higher than those
detected in the control group, suggesting that ribavirin prolonged lung infection, although this
difference was not statistically significant (Table 3). Gross pathology (lung scores) at day 6
revealed substantial lung discoloration in ribavirin-treated mice. The MDD in mice treated
with ribavirin was reduced (Table 3), but the survivor curve was statistically similar to that of
PSS controls (Figure 4). In the second experiment, virus titers were lower than controls in
ribavirin-treated mice on day 6 (Table 4), but 50% of that group also died by 6 d.p.i. (data not
shown).
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The IL-6 concentration in the lungs on 3 d.p.i., was significantly lower (P < 0.05) in mice
receiving Ampligen™ or ribavirin treatment, and slightly lower with UDA compared with
controls (Table 4). EP128533-treated mice showed no difference in IL-6 compared with
controls. The uninfected control group had IL-6 levels of 2200 ± 670 pg/mL, which could be
a result of stress induced by handling mice during daily weights and twice daily treatments.
Therefore, 2200 pg/mL was considered the baseline IL-6 concentration in this study.
Histopathology of mice with varied antiviral treatments showed neutrophil infiltration and
degenerate cells (Table 4). Lesions observed by a board certified pathologist were summarized
in tabular form, and all lesions observed were included. Lungs in mice treated with a protease
inhibitor, EP128533, and cremaphor solvent control appeared to have less overall lesions on
3 d.p.i. than lungs of mice in other treatment groups. Ribavirin-treated lungs had fewer overall
lesions than those of other groups on 6 d.p.i. Macrophage infiltration, lymphocyte infiltration,
and edema were not detected in infected lungs in this experiment, and no hyaline membrane
formation was observed. Histological changes were similar between Ampligen™ treated
groups and untreated control groups.
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In vitro efficacy testing with strain v2163
The v2163 strain was tested in vitro for sensitivity to multiple antiviral compounds. Compounds
were chosen based on their mode of action or purported activity in previous literature. Vero-76
cells were treated with multiple concentrations of each compound then infected with virus, and
the 50% effective concentration (EC50), the 50% cytotoxic concentration (IC50), and the
selective index (SI) for each compound were calculated (Table 5). Compounds with a high
selective index were considered active. The antiviral activity of drugs against v2163 was similar
to that of the same compounds against the Urbani strain (P > 0.05). Infergen™, a consensus
interferon-α (Kumaki et al., 2008), was shown to be highly active, with a 90% effective
concentration of <0.65 μg/mL against both strains and SI values >490. Ribavirin, promazine,
an antipsychotic drug (Barnard et al., 2008), and calpain inhibitor VI (Barnard et al., 2004)
showed no appreciable activity above their cytotoxic concentration (Table 5). EP128533
(Zhang et al., 2006) and UDA were moderately active. Calpain inhibitor IV (Barnard et al.,
2004) was slightly active against both SARS-CoV v2163 and Urbani strains, with a 90%
effective concentration of 12 and 6.4 μg/mL and SI values of 3.9 and 8.1 respectively. The
Virology. Author manuscript; available in PMC 2010 December 20.
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v2163 strain appeared less sensitive to calpain inhibitor IV and EP128533 than strain Urbani,
although the differences were not statistically significant.
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Discussion
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We have developed a new mouse-adapted strain called v2163 that causes increased morbidity
and mortality in BALB/c mice, which the parent Urbani strain does not do. Strain v2163 was
derived from the non-pathogenic Urbani strain of SARS-CoV by serial passage in BALB/c
mice. Mice infected with the v2163 strain were less likely to survive SARS-CoV infection than
Urbani-infected or MA15-infected mice. The MA15 strain appeared less lethal in the current
study than shown by Roberts et al. (2007). However, in the study previously reported, death
was based on 20% weight loss. When 20% weight loss was equated to mortality in the current
work, the results for MA15 were closely similar to previous reports (Table 1). Further, the prior
finding that an inoculum of 103.9 CCID50 of MA15 per mouse was sublethal (Roberts, et al.,
2007) was confirmed in the current work. The reduced lethality of strain MA15 in the current
experiments may also be attributed to the use of 5–6 week old mice rather than 6–8 week old
mice. In the current study, 5–6 week old mice were much less susceptible to MA15 than were
10–11 week old mice (Table 2). SARS-CoV is known to be more fatal in aged patients than
in younger patients (Chen and Subbarao, 2007). Age-related susceptibility to SARS-CoV in
mice has been shown previously with 4 week versus 6 month old mice (Nagata et al., 2008),
with 12–14 month old mice (Roberts et al., 2005), and between 10 week old and 1 year old
mice (Rockx et al., 2007). The lethality of the v2163 virus in younger mice is an advantage for
its use as a convenient model for evaluation of potential antiviral treatments.
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The v2163 genome contained nine mutations compared with the parent Urbani strain, and these
resulted in 10 amino acid residue changes since bp 26133 affects two reading frames. Although
the v2163 strain was developed independently, its genome shared mutations with the
previously created mouse adapted MA15 strain (Figure 2). The spike mutation Y436H was
common to both lethal strains, and is within the receptor-binding motif (Roberts et al., 2007).
The Y436H mutation has been shown to enhance infectivity of recombinant viruses in mice
(Becker et al., 2008), presumably by providing a more favorable interaction with the mACE2
receptor for docking and entry. The v2163 strain had three mutations in the S (spike) region
that were not present in MA15, suggesting that the increased virulence observed with v2163
potentially may be due to binding properties. Moreover, Y442F is a contact interface residue
site that engages the ACE2 receptor, and passage of civet strain SZ16 K479N in human airway
epithelial cells selected for a similar change at this position, shown to enhance SZ16 S
interaction with the hACE2 receptor (Sheahan et al., 2008). Further, in separate work, a Y442L
mutation was seen on a third mouse-adapted strain (MA20) in the same amino acid residue as
the Y442F mutation of v2163 (Frieman, et al. publication in preparation). Interestingly, the
T1181L and N1169D alterations are in the heptad repeat elements in S2 where they could
promote fusion and entry or host range expansion (McRoy and Baric, 2008).
Mutations outside of the spike region also appeared to be important. The mutation in the M
glycoprotein gene (S6L) is near the MA15 E11K mutation that has been associated with
increased production of virus particles from infected cells, presumably by promoting more
efficient assembly and release, although the exact mechanism is unknown (Pacciarini et al.,
2008). The nsp9 E4185D mutation is located near the nsp9 T4184A mutation of MA15, and
likely confers a similar phenotypic difference, presumably increasing virulence. Both lethal
strains had an nsp13 mutation, although it is not known if they confer similar changes to the
protein structure. The fact that independent selections resulted in similar mutation profiles in
target genes supports their role in increased replication and/or pathogenesis. Elucidation of the
effects of these specific mutations may be key to understanding the genotypic variations that
lead to more lethal phenotypes of SARS-CoV and coronaviruses in general. Such knowledge
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could allow rapid synthesis of chimeric viruses for use in evaluating and developing effective
antiviral treatments.
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Multiple cytokines and chemokines expressed in the lungs of BALB/c mice 3 d.p.i. infected
with mouse-adapted SARS-CoV were significantly higher than those found in lungs of mice
infected with the Urbani strain of SARS-CoV (Figure 3). IL-6 and MCP-1 were more strongly
expressed in v2163-infected mice than in MA15-infected mice. IL-6 and MCP-1 have been
observed in human SARS patients (Chen and Subbarao, 2007), and one human study
determined that IL-6, IL-8 and MCP-1 indicated a high risk of death (Jiang et al., 2005).
Therefore, MCP-1 and IL-6, are likely good early indicators of disease outcome in mice. In
contrast, cytokines MIP-1α and RANTES were more elevated in MA15-infected groups than
v2163-infected groups. Since MA15-infected mice had lower mortality than v2163-infected
mice, MIP-1α and RANTES may not be good indicators of disease outcome. When comparing
the mouse cytokine profile to that detected in human SARS patients, the majority of human
studies showed the same profile as seen in mice for IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α,
IP-10 and MCP-1 (Cameron et al., 2008;Chen and Subbarao, 2007;Hsueh et al., 2004;Zhu,
2004)(Table 6). In contrast, IL-1β was not elevated in mouse lungs or in human lungs, but 3
of 5 serum studies reviewed showed elevated IL-1β in human patients. RANTES was elevated
in mouse lungs but not in the human sera. However, uninfected controls had elevated RANTES
levels in mice as well, so the response was not considered important. IFN-γ was detected in
lethally infected mouse lungs but not in human lungs. Nevertheless, the IFN-γ findings were
considered consistent with human data since the IFN-γ level in mice was low, and IFN-γ has
been found in human serum in some studies but not others. The two mouse-adapted SARSCoV strains in this study both resulted in similar cytokine profiles (Figure 3).
IL-6 levels were of particular interest. The increase in IL-6 corresponded directly with an
increase in mortality in the respective experimental groups. Mice infected with the wild-type
Urbani strain showed no signs of disease or death, and they had no IL-6 detected in the lungs,
while v2163-infected mice expressed high levels of IL-6. In one replicate study, 100% of
v2163-infected mice died, and the average IL-6 level for lung homogenates in that group was
2750 pg/mL with only one mouse lower than 2700 pg/mL. The corresponding MA15-infected
group in the same study had 100% recovery after severe illness, and those mice had an average
IL-6 concentration of only 520 pg/mL with no sample higher than 900 pg/mL. Similarly, one
clinical study found that patients with the poorest outcomes also had high levels of IL-6
secreting cells (Jones et al., 2004). In the current work, infected mice receiving PSS, cremaphor
and EP128533 groups showed higher IL-6 concentrations than the ribavirin, Ampligen™ and
UDA groups (Table 4). The lower IL-6 concentration on 3 d.p.i. coincided with treatments that
afforded at least some protection against death in the survival study (Table 3).
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The role of IL-6 in SARS-CoV infection merits further investigation. IL-6 is critical in B-cell
maturation and acute-phase responses (Kopf et al., 1994), and it is critical in coordination of
immune response (Gowen et al., 2006). Conversely, a study reported by Hegde, Pahne, and
Smola-Hess (2004) suggests that IL-6 also has immunosuppressive properties. However, high
expression of IL-6 may exacerbate disease. In SARS patients, damage to the lung seems to be
primarily by viral destruction of alveolar and bronchial epithelial cells and macrophages (Chen
and Subbarao, 2007). However, elevated IL-6 levels and concomitant lung damage continued
even after peak virus production, which suggests that IL-6 contributes to disease progression
(Wang et al., 2004). Furthermore, a SARS patient study showed altered liver function,
leucopenia, lymphopenia, thrombocytopenia, and subsequent respiratory distress syndrome,
suggesting that there was inflammatory damage resulting from SARS-CoV infection (Peiris
et al., 2003a). Studies with other viruses also suggest that excess production of IL-6 may
exacerbate disease. For example, a study of herpes simplex virus (HSV) suggested that
exuberant production of IL-6 in neonates may explain why sepsis syndrome is more common
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with HSV infection in neonates than in adults (Kurt-Jones et al., 2005). A study of phlebovirus
infection also proposed that IL-6 contributes to pathogenesis (Gowen et al., 2006). Regardless
of the cause-effect relationship, we found that IL-6 is strongly expressed in the lungs during
infection with mouse-adapted SARS-CoV virus and may be an effective predictor of disease
outcome.
The histopathology of SARS is difficult to distinguish because most lesions observed with
SARS can be found with many infections. The main distinguishing histopathological factors
in human SARS disease are consolidation, edema, and hyaline membrane formation (Guo et
al., 2008). Also, inflammatory infiltrates, usually comprised of mostly macrophages and
lymphocytes, are disproportionately low in number with respect to the alveolar damage, and
sometimes absent (Chen and Subbarao, 2007; Cheung et al., 2004; Guo et al., 2008). In the
current study, lungs infected with mouse-adapted strains of SARS-CoV showed acute to
subacute alveolitis with some perivascular edema in some sections. Mice lungs had slight to
moderate neutrophil and macrophage infiltration, but lymphocytes were not observed.
Erythrocyte infiltration and some fibrinous material were observed with v2163 in some
experiments not shown. No hyaline membrane was formed in the mouse lungs. Since lung
pathology differed from human disease, and since mice groups that died from infection had
similar pathology to that of treated mice that survived infection (Table 5), we submit that
histopathology will not be an important marker in this SARS model.
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SARS infects multiple tissues in humans, including spleen, intestines, kidneys, liver, adrenal,
parathyroid, pituitary, cerebrum, and pancreas and neurons of CNS (Chen and Subbarao,
2007; Guo et al., 2008). With v2163, infectious virus was consistently found in the lung and
snout of v2163 inoculated mice on day 3 and day 6 post inoculation, but was only rarely seen
in serum. Virus was not recovered from kidney, brain, spleen, intestine, liver, or heart of v2163infected mice with limits of detection of 2.1 log CCID50 for kidney, and 1.1 log CCID50 for
brain, spleen, and heart, and 4.1 log CCID50 for liver and intestine (data not shown). With
MA15, Roberts et al. (2007) reported low titers of infectious virus found in lung, brain, spleen
and liver of mice infected with MA15.
Ribavirin, Ampligen™, EP128533, and UDA treatments were selected to assess the new v2163
strain of SARS-CoV as a model for in vivo evaluation of potential antiviral drugs. These drugs
where chosen to represent a variety of modes of action.
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Ribavirin is a known antiviral compound (Sidwell et al., 1972) with multiple modes of action,
most of which stem from inhibition of inosine monophosphate dehydrogenase (IMPDH)
leading to depressed intracellular GTP levels (Streeter et al., 1973). We had previously found
in a mouse virus lung replication model of SARS-CoV that ribavirin extended the time that
virus could be detected in the lungs of mice (Barnard et al., 2006b), and this was also observed
in one trial of the current study (Table 3). The prolonged high lung titers observed suggested
that ribavirin may contribute to the pathogenesis of SARS-CoV by prolonging and/or
enhancing viral replication in the lungs, allowing continual stimulation of the inflammatory
response, which may contribute to pathogenesis (Perlman and Dandekar, 2005). Also, ribavirin
is known to be somewhat toxic, causing hemolytic anemia and other adverse side effects
(Wong and Yuen, 2008), so ribavirin would presumably exacerbate disease if there were no
concomitant antiviral effect. Interestingly, exacerbation of viral disease by ribavirin has also
been shown with West Nile Virus, resulting in increased mortality in hamsters (Morrey et al.,
2004) and possibly in human patients (Chowers et al., 2001). In contrast, the second experiment
in the current work showed significantly decreased IL-6 concentrations on 3 d.p.i. and
somewhat decreased virus titers in ribavirin-treated animals on 6 d.p.i., suggesting some effect
of ribavirin in mice (Table 4). The IL-6 reduction with ribavirin was interesting in light of
previous reports that ribavirin inhibited IL-6 production in respiratory epithelia cells infected
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with RSV virus (Jiang, Kunimoto, and Patel, 1998) and endothelial cells infected with Dengue
virus (Huang et al., 2000). However, IL-6 was not reduced by ribavirin in activated T-cells
(Hultgren et al., 1998), and ribavirin treatment did not reduce SARS-CoV viral load or IL-6 in
human SARS patients (Wang et al., 2005). Ribavirin has not been shown to be effective against
SARS in humans. In 2006, systematic review and comprehensive summary of treatments used
for SARS patients found that 26 studies with ribavirin were inconclusive and that four showed
possible harm (Stockman, Bellamy, and Garner, 2006). However, a 2008 review stated that
ribavirin treatment combined with protease inhibitors could be useful clinically, although
randomized controlled trials were still needed (Wong and Yuen, 2008). Another study showed
synergy with ribavirin in combination with IFN-β in vitro (Morgenstern et al., 2005).
Additional research is required to draw more certain conclusions about ribavirin in mice,
including age-related studies and drug combination experiments using the lethal v2163 virus
as a model.
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Ampligen™, poly(I:C(12)U), is a synthetic dsRNA polymer that stimulates production of
interferon (Carter et al., 1972; Gowen et al., 2007). Ampligen™ has been shown to be effective
in vivo against multiple viruses, including Coxsackie virus (Padalko et al., 2004), Venezuelan
equine encephalitis (VEE) virus (Julander et al., 2008), punta toro virus (Sidwell et al.,
1994), Modoc virus (Leyssen et al., 2003), duck hepatitis B virus (Niu et al., 1993), Banzi virus
(Pinto, Morahan, and Brinton, 1988), herpes simplex type 2 (HSV-2) virus (Pinto, Morahan,
and Brinton, 1988), and Pichinde virus (Smee et al., 1993). In a virus replication model,
Ampligen™ at 10 mg/kg was previously found to afford protection against SARS-CoV
replication in the lungs (Barnard et al., 2006a). SARS-CoV is known to be sensitive to type I
interferons, IFN-α/β (Cinatl et al., 2003; Stroher et al., 2004). Normally, in the presence of
double-stranded RNA or 5′-triphosphorylated ssRNA such as in viral infection, IFNs are
synthesized and secreted by infected cells and stimulate expression of potent antiviral proteins
(Sadler and Williams, 2008; Samuel, 2001). However, IFN pathways are blocked in cells
infected with SARS-CoV (Frieman, Heise, and Baric, 2008), thus making the host more
susceptible to infection. We believe that exogenous stimulation of IFN pathways with
Ampligen™ overcomes the evasion of virus sensing and signaling pathways. Furthermore,
Kuri et al. suggested that “priming” with small amounts of IFN helps the cells themselves
restore their normal IFN response to SARS-CoV (2009). In the current study, Ampligen™
appeared not to affect virus replication initially, but led to more rapid decline of virus in the
lungs compared with untreated animals by 6 d.p.i. (Table 3). The study showed that
Ampligen™ protected against death and gross damage to the lungs in the presence of lethal
SARS-CoV.
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Stinging nettle lectin (Urtica doica agglutinin, UDA) is an N-acetyl glucosamine-specific lectin
that was reported as efficacious against HIV (De Clercq, 2000). More recently, UDA was
reported to inhibit coronaviruses in vitro with some selectivity (van der Meer et al., 2007a).
Keyaerts et al. (2007) showed that UDA was a potent and selective inhibitor of SARS-CoV
strain Frankfurt-1. Plant lectins like UDA probably target viral attachment and fusion, and
exocytosis or egress of the virus from the cell (Balzarini, 2007; van der Meer et al., 2007b).
The reduction of IL-6 in lungs at 3 d.p.i. along with 50% survival of mice in this study provide
evidence to support further investigation of UDA treatment regiments as potential antiviral
therapies.
Zhang et al. (2006) reported the design and synthesis of a SARS-CoV protease inhibitor
EP128533, 4-(Z-Val-amido)-6-fluoro-5-oxohexanoic acid dimethylamidea, chemical formula
C21H30FN3O5 and molecular weight 423. It was shown to inhibit replication of SARS-CoV
strains FFM1 and 6109 in Vero and CaCO2 cells. In the current study, EP128533 was active
in cell culture against the Urbani and v2163 strains of SARS-CoV (Table 5), but it was not
efficacious in preventing death or reducing the disease signs measured in BALB/c mice (Tables
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3 and 4). Since EP128533 is relatively insoluble, the lack of activity is likely because it is not
bioavailable in the animal. EP128533 in uninfected mice was not toxic, and replicate trials
using DMSO as the solvent yielded similar results as with cremaphor (data not shown).
Nevertheless, based on in vitro results, this compound may be a foundation for an effective
antiviral protease if a prodrug is developed to make it more soluble and bioavailable.
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In vitro sensitivity to antiviral compounds of the v2163 strain was similar to that of strain
Urbani (P > 0.05) when the two strains were tested in parallel against multiple compounds. In
vitro data confirmed recent findings by Barnard et al. (Barnard et al., 2008; Barnard et al.,
2006b) that promazine, an antipsychotic drug, and ribavirin, a nucleoside analog, were not
effective against SARS-CoV in vitro. Findings with v2163 supported prior findings that
Infergen™ was active in vitro against SARS-CoV Urbani (Kumaki et al., 2008). Protease
inhibitor EP128533 was active in vitro, as shown previously (Zhang et al., 2006). The current
in vitro results showed no marked activity with a calpain inhibitor VI, and slight to moderate
activity with calpain inhibitor IV. A previous report showed greater antiviral activity with
calpain inhibitor VI than with calpain inhibitor IV (Barnard et al., 2004), and the differences
were attributed to greater cell sensitivity to drug toxicity in the previous work, inoculum
variation between studies, and stronger virus replication in mammalian cell culture during the
current study. UDA was found to be moderately active with antiviral selectivity (SI = 19–22),
as with previous work (Keyaerts et al., 2007). Therefore, the v2163 strain was shown to be
effective for evaluating antiviral compounds in vitro using microscopic cytopathic effect,
neutral red assays, and virus yield reduction tests. Using the v2163 strain in various in vitro
assays allowed detection of a highly active compound and various inactive compounds. This
will facilitate future analysis of antiviral compounds, since they can be screened in vitro with
the v2163 strain and tested in vivo with the same strain.
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In conclusion, the new v2163 mouse-adapted strain of SARS-CoV was highly virulent in
BALB/c mice 5–6 weeks old, even with infectious doses as low as 103.5 CCID50 per mouse.
Infection with v2163 caused signs of disease, a strong immunological response, and lung
pathology. The v2163 infection largely simulated human disease, except that hyaline
membrane formation was not detected in the lungs, and infectious virus was not found in tissues
outside of the respiratory tract, as is characteristic in human infection (Chen and Subbarao,
2007). Mutations in the virus were consistent with those seen in another mouse-adapted strain,
and these may be useful in identifying genotypic markers for lethality. The v2163 strain
propagated well in cell culture and was shown to be suitable for in vitro screening of potential
antiviral compounds against SARS-CoV. Strain v2163 was used effectively as an in vivo model
to evaluate SARS-CoV therapies, showing that Ampligen™ pretreatment was active against
lethal SARS-CoV infection, and that UDA may have antiviral effects as well. This new model
will facilitate identification of valuable antiviral compounds against SARS-CoV and against
future emerging pathogens related to SARS-CoV.

Materials and Methods
Mice, cells, media
Female BALB/c mice were obtained from Charles River Laboratories (Wilmington, MA).
They were maintained on Wayne Lab Blox and tap water ad libidum. They were quarantined
for >24 h prior to use. Cells used were Vero-76 (ATCC CRL1587), Vero E6 (ATCC CRL1586),
and Vero (ATCC CCL81) cells maintained in MEM supplemented with 10% fetal bovine
serum (FBS) and no antibiotics. For virus titer tests, MEM with 2% FBS and 50 μg/mL
gentamicin was used.
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Ribavirin was provided by ICN Pharmaceuticals (Costa Mesa, CA). Calpain inhibitor IV and
calpain inhibitor VI were obtained from CalBiochem (San Diego, CA). Infergen™ was
interferon alfacon-1 lot 002586 kindly provided by Intermune, Inc. (Brisbane, CA) in 27 μg/
mL solution and held frozen until tested. Ampligen™ from Hemispherx Biopharma, Inc. was
obtained through the NIAID Antiviral Substances Program. Promazine HCl was obtained from
Sigma Chemical Corporation (St. Louis, MO). EP128533 was obtained from Epicept
Corporation (San Diego, CA) and through the NIAID Antiviral Substances Program. Stinging
nettle lectin (UDA) was obtained from EY Laboratories, Inc. (San Mateo, CA). Compounds
were suspended in DMSO or purified water at 20 mM, then diluted in minimal essential
medium (MEM) as needed for in vitro assays. Compounds for in vivo assays were diluted in
saline, except protease inhibitor EP128533, which was diluted in a cremaphor vehicle (10%
cremaphor, 10% ethanol, 80% purified water).
Viruses
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MA15 virus—The MA15 strain of SARS-CoV mouse-adapted virus was kindly provided by
Dr. Kanta Subbarao, National Institute of Health, NIAID, designated “MA-15 3A-1 P1 in Vero
cells 4/25/2005.” For cytokine and lung pathology, MA15 virus was infected into BALB/c
mice, then the mouse lung homogenates containing the virus were filtered and subcultured
again in Vero (ATCC CCL-81) cell culture for 2 days. Cell culture homogenates were sonicated
then frozen at −80°C. For all other in vivo work, the MA15 virus was subcultured in Vero E6
cells in MEM with 10% FBS, 1 mM sodium pyruvate and 0.1 mM non-essential amino acids.
After a two day incubation, cell culture homogenates were sonicated, centrifuged to clarify the
solution, then aliquotted and held frozen at −80°C. Subcultured stocks were verified by PCR
using primers flanking characteristic mutations.
Urbani virus—Severe acute respiratory syndrome coronavirus (SARS-CoV), strain Urbani
(200300592), was obtained from the Centers for Disease Control and Prevention (CDC,
Atlanta, GA) and routinely passaged in Vero 76 cells.
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Mouse-adapted SARS-CoV v2163—Three BALB/c mice were anesthetized with
Ketamine/Xylazine mixture (approximately 100 mg/kg + 5 mg/kg respectively) and infected
with 50 μL or 100 μL of SARS-CoV Urbani virus solution by nasal inhalation. Three or five
days after infection, mice were euthanized, and the lungs were removed and homogenized in
5 mL of MEM + 10% FBS. The homogenate was tested for virus titer by CPE endpoint dilution
assay, then re-infected into a subsequent group of mice. These infection steps continued for 25
passages, five passages with the homogenate diluted 1/5, then 20 additional passages without
dilution of the lung homogenate between groups. This was determined to be valid because
control mice demonstrated no notable effect from inhalation of uninfected lung tissue. One
interim passage, P-12, was plaque purified. Passages ceased when increased virus titer in the
lungs and signs of illness were observed in the infected animals. Lung homogenate from
passge-25 mice was filtered and subcultured in Vero 76 cells, then diluted and plated to isolate
single plaques. Plaque purification in Vero76 cells was repeated 3 times. Four isolated plaques
were subcultured in Vero-76 cells then compared by infecting into BALB/c mice. The most
virulent isolate was selected. Aliquots of the virus stock were incubated in MEM medium for
seven days and demonstrated no growth of extraneous bacteria or fungi. RNA was isolated
from the virus stock using the RNA-easy kit (Qiagen, Alameda, CA) and tested by qRT-PCR
with two primer pairs to verify the presence of SARS-CoV sequences (Accession
#AY278741). The presence of SARS-CoV antigen in the virus stock was also demonstrated
using the SARS-CoV Ag Detection kit (Wantai Inc., China). The new virus stock was
designated “SARS-CoV USU strain v2163” and was used for subsequent studies. It is hereafter
referred to as v2163.
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Sequence analysis was then performed at the University of North Carolina. RNA was purified
from the cell lysate of Vero-76 cells infected with SARS-CoV V2163 using the RNAeasy kit
(Qiagen, Alameda, CA) followed by first-strand cDNA synthesis by reverse transcription using
Superscript II (Invitrogen, Carlsbad, CA) as per the manufacturers’ protocol. Reverse
transcription was performed with an initial incubation of 65 °C for 5 min then cooled on ice
followed by a 50-min incubation at 42 °C and a 5-min denaturation at 70 °C. Two microliters
of each cDNA reaction were amplified by PCR using Accuprime High Fidelity Taq Polymerase
(Invitrogen, Carlsbad, CA). Fifteen pairs of primers were used to generate the overlapping PCR
products spaced every 2.5 Kb generating DNA fragments with 500 bp overlap at each end.
Amplification products were visualized on agarose gels and purified by use of the QIAquick
Gel Extraction Kit (Qiagen, Alameda, CA). PCR products were sequenced in both forward and
reverse directions with primers spaced every 500 bp along the genome. Automated sequencing
was performed utilizing the BigDye Terminator version 3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA) as per manufacturer’s instructions on an ABI Prism 3730 DNA
Analyzer (Applied Biosystems). Sequences were assembled and analyzed with Vector NTI
and Auto Assembler DNA Sequence Assembly Software (ABI Prism; Applied Biosystems).
When a mutation was identified in comparison with the SARS-CoV published sequence
(Urbani accession #AY278741), independent RT-PCR reactions were run and subsequent RTPCR products were sequenced through the region containing the putative mutation to confirm
the mutation.
Mouse virulence studies
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Mice 5–6 weeks old (14–16 grams) were separated into groups of 10 mice for sacrifice on days
3 and 6 post infection, and 9 or 10 mice for weight and survival data. Mice were anesthetized
by 0.1 mL intraperitoneal injection of ketamine (100 mg/kg)/xylazine (5 mg/kg) and then
infected intranasally with a 50 μl suspension of the virus. Mice were inoculated with
approximately 105.5, 104.5, and 103.5 CCID50 of v2163 or MA15. Plaque assays were
performed in Vero 76 cells on the actual inocula after infection and showed that the MA15
virus titer was equal or higher than that of the corresponding v2163 titer for both replicate
experiments. As a wild type control and for comparison, mice were inoculated with
approximately 105 CCID50 of the Urbani SARS-CoV strain. Groups of 5 and 10 mice were
sham infected with MEM as a negative control. The groups of 10 survival mice were weighed
individually to the nearest 0.1 gram each day, and observed daily for death. Animals were held
until death naturally occurred or up to 21 d.p.i. Three days and 6 d.p.i., 5 survivors in each
group were euthanized and the lungs removed. Lungs were then diluted 1:20 in MEM + 10%
FBS, homogenized, and held at −80 °C for virus titer testing. Lung homogenates were later
thawed and serially diluted in MEM + 2% FBS in triplicate in 96-well plates to obtain
CCID50 values by the endpoint dilution method described below for virus yield reduction
assays. The mean day of death (MDD) was calculated using mice that died and excluding
survivors. The study was repeated in 5–6 week old mice and also performed once in 10–11
week old (17–21 gram) mice. Another study was performed as above, with just the 104.5
inoculum in BALB/c mice of various ages to determine the age-dependent susceptibility to
lethal infection.
Cytokine and chemokine analysis
Groups of 15 mice (14–18 g) were inoculated intranasally with the three virus strains suspended
in 50 μL of MEM solution, and controls were mock infected with saline. Inocula (CCID50 per
mouse) were 4.1 ± 0.3 log CCID50 for Urbani, 4.2 ± 0.4 for v2163, and 4.0 ± 0.5 for MA15.
On day 3 post virus exposure, five surviving mice were euthanized and the lungs harvested.
Remaining mice were held for measurements of weight loss and death. Lung sections were
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saved for histopathology in formalin solution. The remaining lung section was diluted 1:20 in
MEM solution and homogenized, then held frozen at −80 °C. Samples were then tested for
cytokines IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, TNF-α, GM-CSF and INFγ, and for chemokines MIP-1α, MCP-1, and RANTES using the Q-Plex™ mouse cytokine
array screen (Quansys Bioscience, Logan, Utah), a quantitative ELISA-based test with multiple
distinct capture antibodies absorbed to each well of a 96-well plate in a defined array. Cytokines
were quantified by relative luminescence of each spot in the array, and values (pg/mL)
calculated using the concurrently-run Quansys Bioscience™ standard curve and the
QuansysAnalysys™ software (version 3.4). In one replicate some MCP-1 and RANTES values
exceeded the standard curve range and were estimated by extrapolation (Figure 3). Two of ten
v2163-inoculated mice had abnormally low cytokines and were excluded as outliers because
they had little or no virus detected in the lungs. The cytokine results from all mice from the
two experiments were combined for averages, standard deviation, and Kruskal-Wallis analysis
of variance followed by Dunn’s multiple comparison test compared to Urbani-infected mice.
Histopathology
Groups of animals were infected as described for the cytokine assay above. After three days,
lungs from sham controls and mice exposed to 104 CCID50 Urbani, 104 v2163, 105 MA15 and
were formalin-fixed. Three lungs from each group were sectioned and stained with H&E stain
and evaluated by a board certified veterinary pathologist for histopathological changes.
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In vivo efficacy of drugs against v2163 infection

NIH-PA Author Manuscript

Groups of mice (16–19 g) were inoculated with 50 μL containing 104.0–104.4 CCID50 of v2163
virus by the i.n. route. Groups of mice were administered 100 μL of the following drugs by the
intraperitoneal (i.p.) route: ribavirin 32.5 mg/kg twice a day 8 hours apart for 4 days beginning
4 hours prior to exposure to virus; Ampligen™ at 5 mg/kg for 4 treatments 12–16 hours apart
beginning 16 hours before virus exposure; and physiological saline solution (PSS) as a placebo
using the dosing regimen described for ribavirin. In separate studies, 16–18 g mice were treated
with UDA at 5 mg/kg/d using the treatment regiment described above for ribavirin, and 18–
20 gram mice were treated with 30 mg/kg/d of EP128533 protease suspended in 10%
cremaphor administered b.i.d. as above for 5 days beginning at time of infection. Mice for
toxicity controls were treated with PSS or cremaphor diluent using the treatment regimes
described above but without virus exposure. Mice were observed daily, and group weights
were taken periodically throughout the test period. The average weight loss was calculated on
3 d.p.i., and significance between treatments evaluated by one-way analysis of variance
followed by Newman-Keuls multiple comparison test. Compound toxicity in uninfected mice
was evaluated in terms of weight change and adverse events, and no drug toxicity was observed
in this study.
On days 3 and 6 post infection, three to five surviving mice from each treatment group were
sacrificed. The remaining mice were held and observed for death up to day 14 post virus
exposure (10 days for UDA). Animals that lost greater than 30% of their initial body weight
in this experiment were humanely euthanized and the day of euthanasia was designated as the
day of death. Lungs from sacrificed mice were observed for gross pathology and discoloration
and assigned a score ranging from 0 (normal appearing lung) to 4 (maximal plum coloration
in 100% of lung). Mouse lung samples from each test group were pooled and homogenized in
MEM solution and assayed in duplicate for infectious virus using the method described below
for virus yield assays using triplicate wells of Vero 76 cells. Titers were compared to controls
by analysis of variance on log-transformed values assuming equal variance and normal
distribution.

Virology. Author manuscript; available in PMC 2010 December 20.

Day et al.

Page 14

NIH-PA Author Manuscript

The procedures above were repeated in 15–18 gram mice for IL-6, histopathology, and virus
titers in lungs and multiple tissues on 3 and 6 d.p.i. Lung sections were placed in formalin and
examined for histopathology as described above. Remaining lung portions were homogenized
individually in 2 mL of MEM + 10% FBS and held frozen at −80°. Samples were thawed,
mixed, and then tested for IL-6 levels using the eBioScience (San Diego, CA) IL-6 ELISA kit
per manufacturer’s instructions. Samples size was three per treatment group for histopathology,
4 or 5 for IL-6 and virus titer depending on number of survivors remaining. Values in pg/g of
lung were converted to pg/mL corresponding with the 1/20 dilution used in the initial untreated
mice (Figure 3). A low outlier in saline day 3 (655 pg/mL) was included in results but excluded
from statistical analysis. IL-6 levels in treated groups were compared to untreated controls by
ANOVA with Newman-Kuels pairwise comparisons. Individual tissues were harvested with
separate sterile instruments to ensure that each tissue was isolated from the lung during
necropsy. Tissues were homogenized and titers performed as described for lungs above.
In vitro efficacy testing with strain v2163
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The antiviral activity of test compounds was evaluated using the v2163 mouse-adapted virus
strain as an in vitro model compared with strain Urbani run concurrently. Antiviral activity
was measured by inhibition of virus-induced cytopathic effect (CPE) (Sidwell and Huffman,
1971), neutral red (NR) dye uptake (McManus, 1976), and also by virus yield reduction assays.
Vero-76 (ATCC CRL 1587) cells grown in MEM with 10% fetal bovine serum (FBS) were
seeded into 96-well plates at a concentration of 2 × 104 cells per well and grown overnight at
37°C with 5% CO2. Test compounds were dissolved in DMSO or water, then serially diluted
in MEM by half-log dilutions in triplicate wells. Test wells were infected with a multiplicity
of infection (MOI) of less than 0.007 CCID50 per cell, sufficient to cause near complete
cytopathic effect (CPE) in three days, which was 1.6 to 2.1 log CCID50 per well for Urbani,
and 1.0 to 2.4 log CCID50 per well for v2163. The test medium was MEM with 2% FBS and
50 μg/mL gentamicin. Toxicity of compounds was assayed in duplicate wells without virus.
Plates were incubated as above for three days, then each well read microscopically for CPE.
Cells were incubated with 0.011% NR dye for two h at 37 °C. Free dye was removed from the
wells, then the uptaken dye was eluted with 50% ethanol in Sorensen citrate buffer for >30
min. Absorbance was then measured as described by Finter (1969), with an Opsys MR
microplate reader (Dynex, Chantilly, VA) at 540 and 405 nm. Absorbance values and visual
CPE were expressed as percentages of cell controls and untreated virus controls, adjusted for
toxicity. The 50% effective concentration (EC50) and 50% inhibitory concentration (cytotoxic,
IC50) values were calculated by regression analysis.
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Virus yield reduction assays were performed using the cell culture 50% infectious dose
(CCID50) assay essentially as described previously (Smee et al., 1992). Briefly, supernatants
from each well were serially diluted in triplicate wells of 96-well plates containing Vero-76
cells. Plates were incubated six days and then checked for virus-induced CPE. Quantitation of
virus yield titers was by the end point method of Reed and Muench (1938). The EC90 value
was calculated using linear regression to estimate the concentration necessary to inhibit virus
yield by 90% or a one log10 decrease in virus titer. Results of at least three assays were averaged
and activity with the two virus strains was compared by student’s t test.
Statistical analyses
Statistical analyses were performed using PRISM™ 5.01 for Windows, PRISM™ 4.0c for
MAC (GraphPad Software, Inc., La Jolla, CA), and Microsoft Excel 11.5. Comparisons not
otherwise detailed were performed by the student’s two-tailed t-test assuming normal
distribution and equal variance, and more sophisticated analyses performed if differences were
observed. The Kolmogorov-Smirnov test (KS test) for normal distribution and Bartlett’s test
for equal variance were performed as applicable. MDD, cytokine values, and gross lung score
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data were analyzed by Mann-Whitney pairwise comparisons or the Kruskal-Wallis test
followed by Dunn’s multiple comparison test as applicable. Surviving animals were not
included in MDD calculations. Raw survival numbers were compared by the Fisher exact test.
Survivor curve analysis (as in Figure 1) was done using the Kaplan-Meier method and a log
rank test. When that analysis revealed significant differences among the treatment groups,
pairwise comparisons of survivor curves were analyzed by the Gehan-Breslow-Wilcoxon test,
and the relative significance was adjusted to a Bonferroni-corrected significance threshold for
the number of treatment comparisons made. Differences in percent weight loss were tested by
one-way ANOVA with Newman-Keuls multiple comparison test, assuming equal variance and
normal distribution. For lung titer data, we performed a KS test for normality, then used nonparametric Kruskal-Wallis test with Dunn’s multiple comparison test for groups that were not
normally distributed, and a one-way ANOVA with Newman-Keuls multiple comparison test
for groups that were normally distributed. LD50 was calculated using Probit analysis (StatPlus:
MAC 2009).
Ethics and biosafety
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This study was conducted in accordance with the approval of the Institutional Animal Care
and Use Committee of Utah State University dated 21 September, 2004. The work was done
in the AAALAC-accredited Laboratory Animal Research Center of Utah State University. The
U. S. Government (National Institutes of Health) approval was renewed 27 February 2002
(Assurance no. A3801-01) in accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals (Revision; 1996). By special provision, animals for
lethality comparisons were allowed to survive without compassionate euthanasia until death
naturally occurred in order to distinguish weight loss and mortality. All experiments involving
infectious SARS-CoV were carried out in BSL-3+ laboratories, and all personnel wore
complete body protective coverings and HEPA-filtered powered air purifying respirators.
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Figure 1.

Percent survival of 5–6 week old BALB/c mice infected with SARS-CoV strains Urbani,
v2163, and MA15. ***P <0.001 MA15 compared with v2163.
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Figure 2.

Mutations found in v2163 and MA15 mouse-adapted strains of SARS-CoV compared with the
Urbani strain.
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Figure 3.

Average cytokines detected in BALB/c mice lungs 3 days after infection with various strains
of SARS-CoV (n ≥ 8). Black bars are v2163, gray bars are MA15, striped bars are Urbani, and
white bars are uninfected controls. *P < 0.05, **P < 0.01, ***P < 0.001 MA15 compared with
Urbani.
aLower limit of detection
bThe v2163 and MA15 averages included some extrapolated values that were minimum
estimates.
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Figure 4.

Histological slides showing representative lung pathology; a) Urbani- infected lung with no
significant changes (40×); b) MA15-infected lung with small numbers of foamy macrophages
that widen scattered alveolar septae (40×), c) MA15-infected lung with rare individual
bronchiolar lining cells that were swollen and hypereosinophilic, and scattered alveolar septae
widened by foamy macrophages (40×), d) v2163-infected lung with moderate numbers of
neutrophils and edema fluid surrounding several large vessels (40×), e) v2163-infected lung
with small numbers of alveolar macrophages throughout airspaces (60×), and f) uninfected
lung with no significant changes (40×).
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Figure 5.

Effects of Ampligen™, ribavirin, EP128533, and UDA on survival of BALB/c mice infected
with SARS-CoV strain v2163.
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7.8 ± 0.3
7.9 ± 0.3
6.6 ± 0.3
6.7 ± 0.1*
6.9 ± 0.2
5.8 ± 1.1
<3.8

nta
6.2 ± 2.6
7.3 ± 0.6
nta
4.8 ± 1.1b
6.3 ± 0.7
<3.8
<3.8

Lung Titer 3 dpi (Log CCID50/Lung Titer 6 dpi (Log CCID50/
Mice losing 20% of
Weight
% Weight Change 4 dpi
g)
g)

Mortality, lung virus titer, and weight loss of 5–6 week old BALB/c mice infected intranasally with the Urbani strain and two mouse-adapted strains of
SARS-CoV.
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P < 0.001 MA15 compared with corresponding dilution of v2163

Mean day of death; animals surviving to the end of the study were excluded

a

***

P < 0.05,

−24 ± 3.6
−23 ± 3.8
−26 ± 3.1
−25 ± 3.5
−28 ± 1.6**
−23 ± 3.4
−0.5 ± 2.3
0 ± 2.4

105.5
104.5
103.5
105.5
104.5
103.5
105.0
None

v2163
v2163
v2163
MA15
MA15
MA15
Urbani
Uninfected

*

% Weight Change (4 dpi)

Inoculum (~CCID50)

SARS Strain
0/10
1/10
2/10
8/10*
4/10
10/10***
10/10
5/5

Survival

5–6 week old mice

4.5 ± 0.7
5.9 ± 1.4
6.4 ± 1.9
3.5 ± 3.5
13.5 ± 6.9
N/A
N/A
N/A

MDDb
−18 ± 1.2
−17 ± 5.0
−20 ± 2.0
−22 ± 2.1
−23 ± 2.4***
−24 ± 1.4*
−2.3 ± 2.2
−2.3 ± 2.5

% Weight Change (4 dpi)
0/10
1/10
0/10
1/10
3/10
9/10***
10/10
5/5

Survival

10–11 week old mice

4.8 ± 1.8
5.7 ± 1.0
7.3 ± 0.7
6.8 ± 1.4
8.6 ± 3.9
14 (n = 1)
N/A
N/A

MDDa

Death and weight comparisons of 5–6 week and 10–11 week old BALB/c mice infected intranasally with v2163, MA15, or Urbani strains of SARS-CoV.
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1/15
0/10

Cremaphorc
EP128533c 30 mg/kg/day

c
Separate experiment with 10% cremaphor as diluent instead of saline

Separate experiment with 10 day duration versus normal 21 days

Mean weight difference evaluated on day 3 post virus exposure

b

a

4.3 ± 1.3
4.5 ± 1.4

6.2 ± 1.7
4.5 ± 0.84*
>14***
6.6 ± 2.0

Mean Day of Death ±
SD

NT
NT

3.2 ± 0.58
2.5 ± 0.94
0.90 ± 0.89*
2.17±0.29

Lung score 6 dpi

P<0.001 compared with saline or cremaphor control NT = not tested, all mice died before day 6

***

P< 0.05,

0/10
3/10
10/10***
5/10*

Normal Saline
Ribavirin 75 mg/kg/day
Ampligen™10 mg/kg/day
UDAb 5 mg/kg/day

*

Survivors/Total

Treatment

8.1 ± 0.23
8.2 ± 0.14

7.0 ± 0.11
7.0 ± 0.24
7.6 ± 0.52
7.32± .07

−3.4 ± 2.7
−1.6 ± 1.4*
0.50 ± 0.78***
−2.3 ± 0.14
−2.6 ± 0.35
−3.2 ± 0.28

Lung Titer 3 dpi (Log
CCID50/g)

Weight change (grams)a

NT
NT

5.9 ± 1.4
7.0 ± 0.82
4.3 ± 0.16
6.6 ± 0.93

Lung Titer 6 dpi (Log
CCID50/g)

Survival, mean day of death, lung scores, weight change, and virus titers in BALB/c mice infected with mouse-adapted SARS-CoV v2163 and treated with
ribavirin or Ampligen™.
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6
6
6
6
6
6

Saline Control
Ribavirin (75 mg/kg/d)
Ampligen™ (10 mg/kg/d)
UDA (5 mg/kg/d)
EP128533 (30 mg/kg/d)
Cremaphor control

6.8 ± 0.85
5.0 ± 1.7
6.2 ± 1.5
7.0 ± 0.32
nt
nt

<2.8
7.7 ± 0.63
7.7 ± 0.21
8.0 ± 0.39
7.9 ± 0.84
8.2 ± 0.14
8.1 ± 0.23

Lung Titer (Log
CCID50/g)

Small to moderate numbers of neutrophils in alveoli or surrounding scattered vessels

2
0
3
3
nt
nt

0
3
2
3
3
0
1

Neutrophilsb

2
2
3
3
nt
nt

0
3
2
3
3
1
1

Histiocytesc

1
0
3
3
nt
nt

0
2
2
3
3
0
1

Widened Alveolid

e
Terminal bronchioles contain luminal degenerate and necrotic cellular debris, or are lined by individual degenerate or necrotic epithelial cells and/or necrotic cell debris

Widened groups of alveolar septae

d

c
Small to moderate numbers of histiocytes in alveoli

b

Days post inoculation

a

2140 ± 560
2320 ± 820
1590 ± 380
2530 ± 1760
nt
nt

2200 ± 670
3880 ± 2210
2230 ± 610*
1650 ± 580*
3330 ± 1340
4690 ± 1520
5000 ± 1990

IL-6 (pg/mL)

0
0
0
0
nt
nt

0
3
1
0
2
1
1

Degenerate/Necrotice

P < 0.01, by Wilcoxon analysis compared to untreated control (excluding 655 pg/mL outlier in PSS day 3) nt = not tested because all mice from this group died before day 6

**

P < 0.05,

3
3
3
3
3
3
3

Saline, Uninfected
Saline
Ribavirin (75 mg/kg/d)
Ampligen™ (10 mg/kg/d)
UDA (5 mg/kg/d)
EP128533 (30 mg/kg/d)
Cremaphor control

*

Daya

Treatment

Summary of Histopathology (inclusive)

Lung IL-6 levels and pathology in BALB/c mice 3 days and 6 days after infection with SARS-CoV strain v2163 and treatment with Ampligen™, ribavirin,
UDA, or EP128533.
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EC50b μg/mL
66 ± 43
63 ± 36
2.6 ± 1.1
2.1 ± 1.0
14 ± 5.4
13 ± 2.9f
4.1 ± 3.5
0.87 ± 0.13
<0.12
<0.29
>240
>240
0.70 ± 0.22
0.62 ± 0.26
1.4 ± 1.1
0.56 ± 0.57

Inoculuma
102.2
101.9
102.2
101.9
102.2
101.9
102.2
101.9
101.9
101.6
101.7
101.7
101.7
101.7
102.0
101.8

50% effective antiviral concentration.

f
Two replicates only.

e
Selective index: SI = IC50/EC50, and virus yield SI = IC50/EC90.

In vitro 90% effective antiviral concentration by virus yield assay.

d

c
50% cell inhibitory concentration of drug without virus.

b

Average CCID50 virus per well from 3 replicates.

Ribavirin
Ribavirin
Promazine
Promazine
Calpain VI Inhibitor
Calpain VI Inhibitor
Calpain IV Inhibitor
Calpain IV Inhibitor
Infergen™
Infergen™
Ampligen™
Ampligen™
UDA
UDA
EP128533
EP128533

v2163
Urbani
v2163
Urbani
v2163
Urbani
v2163
Urbani
v2163
Urbani
v2163
Urbani
v2163
Urbani
v2163
Urbani

a

Compound

Virus Strain
>1000
>1000
6.4 ± 2.3
7.9 ± 3.4
>37
>37
>56
>56
>320
>320
>240
>240
>10
>10
>100
>100

IC50c μg/mL

Visual Assay

15
16
2.5
3.8
2.6
2.8
14
64
>2700
>1100
1.0
1.0
14
16
>71
>180

SI
80 ± 74
86 ± 50
8.0 ± 7.2
3.4 ± 2.1
17 ± 7.3
14 ± 10f
9.5 ± 9.2
4.3 ± 4.5
<0.11
<0.31
>240
>240
0.86 ± 0.39
0.76 ± 0.22
1.6 ± 1.6
1.3 ± 2.1

EC50 μg/mL
200 ± 92
99 ± 51
7.3 ± 4.2
8.1 ± 3.0
37 ± 5.1
27 ± 4.4
48 ± 19
52 ± 18
>320
>320
>240
>240
21 ± 9.5
21 ± 9.5
>100
>100

IC50 μg/mL

Neutral Red Assay

2.5
1.7
0
2.4
2.1
1.9
5.1
12
>2800
>1000
1.0
1.0
24
27
>61
>75

SI

In vitro antiviral activity of various compounds in vitro against SARS-CoV Urbani and a mouse-adapted strain of SARS-CoV.

83 ± 63
104 ± 84
3.9 ± 2.2
3.1 ± 2.1
24 ± 7.9f
15 ± 1.0f
12 ± 2.6f
6.4 ± 2.6f
<0.65
<0.65
>240
>240
1.1 ± 19
0.95 ± 0.36
12 ± 9.4
5.3 ± 3.7

EC90d μg/mL

2.4
1.4
1.9
2.6
1.5
1.7
3.9
8.1
>490
>490
1.0
1.0
19
22
>8.5
>19

SIe

Virus Yield Reduction
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Table 6

Cytokine responses during SARS-CoV infection of lethally-infected mice compared to humans with SARS
disease.
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Cytokine

Lungs of lethally-infected
mice

Human lungsa (number of studies)

Human Serumb (Number of studies
reviewed)

IL-1α

+

ND

ND

IL-1β

0

0 (1)

0 (2)
+ (3)

IL-2

0

0 (1)

0 (5)
+ (2)

IL-3

0

IL-4

0

0 (1)

0 (5)

IL-5

0

ND

ND

IL-6

+

+ (1)

0 (2)
+ (6)

IL-9

0

ND

ND

IL-10

0

0 (1)

0 (6)
+ (1)

IFN-γ

+

0 (1)

0 (2)
+ (4)

TNF-α

0

0 (1)

0 (7)
+ (3)

GM-CSF

0

ND

ND

MCP-1

+

+ (1)

0 (1)
+ (4)

MIP-1α

+

ND

ND

RANTES

+

ND

0 (4)

+ (2)

+ (5)

IP-10
+c
+ = cytokine elevated 0 = cytokine not elevated ND = not determined
a

Source: Chen and Subbarao, 2007

b

Sources: Hsueh et al., 2004; Cameron et al., 2008, Review of Chen and Subbarao, 2007, review of Zhu, 2004.

c
Separate study currently in press.
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